BackgroundDespite advances in therapies that have increased the duration of post-diagnosis survival, living with long-term adverse effects of cancer and its treatment is common. This study aims to evaluate satisfaction with care (SC) as a dimension affecting Health-Related Quality of Life (HRQoL) among people with cancer, considering other sociodemographic and clinical variables supposedly impacting HRQoL.MethodsThis cross-sectional study used an ad hoc form to collect sociodemographic and clinical variables. The SF-12 and TPQ were used to evaluate HRQoL and SC, respectively. The relation between SC, socio-demographic, clinical variables (predictors), and HRQoL (criterion) was assessed using hierarchical linear regression, controlling for age, cancer stage, and time of care.Results263 patients (49.8% males; age 61.2 ± 13.8 years) from two cancer units. Positive correlations (p<0.05) between SC and HRQoL. Females have a poorer HRQoL than males (ß= .416, CI 95% [.162;.671], p=0.001), as well as patients from the hospital ward compared to those in the day hospital service (ß= -.459, CI 95% [-.782 -.137], p=0.005). Greater SC referred to the service features predict better HRQoL (ß= .338, CI 95% [.154;.523], p<0.001).ConclusionsGiven the cross-sectional design, causal inferences cannot be drawn; however, identifying satisfaction with care and other factors associated with HRQoL among people with cancer may help inform prevention and rehabilitation programs.

Anti-angiogenic drugs represent a milestone of metastatic colorectal cancer (mCRC) pts) treatment. To date, no validated prognostic biomarkers are available. Recently, hematological parameters became of particular interest in solid tumors, including mcRC. Here, we present the results of our research in order to identify potential prognostic factors among clinical and laboratory parameters in mCRC pts receiving anti-angiogenic agents at our Centre. We retrospectively collected clinical and laboratory data of mCRC pts treated with anti-angiogenic drugs at the Medical Oncology Unit of Cagliari University Hospital (2018-04/2024) in order to identify a potential prognostic tool. Statistical analysis was performed with MedCalc (survival distribution: Kaplan-Meier; survival comparison: log-rank test; cut-off: ROC curves). Globally, 42 mCRC pts were included in our study. 25 were male, 17 female; 17 had a RAS wild-type tumor, 30 had a left-sided primary). 14 pts received anti-angiogenic agents in the the first-line, 15 in the second-line (4 bevacizumab and 11 aflibercept) and 13 in the first and further lines. Median OS was 31.4 months (95% CI: 18.3 -39.5). When assessing the correlation between clinical and laboratory parameters and prognosis of the study population, a statistically significant improvement in overall survival (OS) was found in patients with platelet to lymphocyte ratio (PLR) equal or lower than 179.23 (31.4 months [95% CI: 20.3-47.1] versus 10.5 months [95%: CI 6.8 - 39.5], p=0.0315, HR= 0.27) and platelet count equal or lower than 360/μl (31.4 months [95% CI: 20.3-41.8] versus 10.3 months [95%: CI 6.8-10.5], p<0.0001, HR=0.0002). Then, according to these findings, we separated pts in two prognostic groups: good prognostic group (no unfavorable variables) and poor prognostic group (≥1 unfavorable variables). We observed a trend for longer OS in patients belonging to the good prognostic group (31.4 months [95% CI: 20.3-41.8] versus 10.5 months [95% CI: 6.8 - 39.5], p=0.0521, HR=0.3166). Our research showed a promising prognostic role of baseline platelet count and PLR in mCRC patients receiving with anti-angiogenic drugs in a limited population at our center. Platelet to lymphocyte ratio and platelet count: new frontiers as prognostic factors in metastatic colorectal cancer patients receiving anti-angiogenic drugs. Platelet to lymphocyte ratio and platelet count: new frontiers as prognostic factors in metastatic colorectal cancer patients receiving anti-angiogenic drugs [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 4653.

Background Alcohol consumption is a potentially modifiable risk factor for breast cancer (BC). Reducing alcohol consumption within the daily amount at low-risk for alcohol-related consequences (daily alcohol threshold) may contribute to preventing BC new cases. However, most women are unaware of risk factors for BC, the daily alcohol threshold, and how to measure alcohol use. We aimed at investigating the efficacy of accessing an interactive website in increasing the knowledge that alcohol is a BC risk factor. Methods We conducted a randomized controlled trial among women waiting for mammography. Women completed a questionnaire to investigate their knowledge before and after accessing an interactive (intervention group) and non-interactive (control group) website. Results We recruited 671 women, randomized 329 (49.0%) and 342 (51.0%) to the intervention and control groups, respectively. At baseline, most women were not aware of most modifiable BC risk factors. Accessing either website significantly increased the percentage of women who acquired the knowledge on BC risk factors, with the interactive website achieving better results: 82% and 69% of women acquired the knowledge that alcohol is a risk factor for BC in the intervention and control groups, respectively (p<0.001). Among women with lower levels of education, the probability of acquiring this knowledge was higher in the intervention group than control group. Conclusion Our results show that accessing an interactive website may increase the percentage of women who acquire the knowledge that alcohol is a BC risk factor especially among women of lower levels of education.

Colorectal cancer (CRC) is a leading tumor worldwide. In CRC, the angiogenic pathway plays a crucial role in cancer development and the process of metastasis. Thus, anti-angiogenic drugs represent a milestone for metastatic CRC (mCRC) treatment and lead to significant improvement of clinical outcomes. Nevertheless, not all patients respond to treatment and some develop resistance. Therefore, the identification of predictive factors able to predict response to angiogenesis pathway blockade is required in order to identify the best candidates to receive these agents. Unfortunately, no predictive biomarkers have been prospectively validated to date. Over the years, research has focused on biologic factors such as genetic polymorphisms, circulating biomarkers, circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and microRNA. Moreover, research efforts have evaluated the potential correlation of molecular biomarkers with imaging techniques used for tumor assessment as well as the application of imaging tools in clinical practice. In addition to functional imaging, radiomics, a relatively newer technique, shows real promise in the setting of correlating molecular medicine to radiological phenotypes.

Immunotherapies have revolutionized cancer treatment approaches. Because not all patients respond positively to immune therapeutic agents, it represents a challenge for scientists who strive to understand the mechanisms behind such resistance. In-depth exploration of tumor biology, using novel technologies such as omics science, can help decode the role of the tumor immune microenvironment (TIME) in producing a response to the immune blockade strategies. It can also help to identify biomarkers for patient stratification and personalized treatment. This review aims to explore these new models and highlight their possible pivotal role in changing clinical practice.

To the Editor: Almost a year after we presented a rare case of primary endometrial squamous cell carcinoma (PESCC) characterized by PAX8 positivity, abnormal p53 expression, and p16 negativity 1, we saw a second case showing new peculiarities and challenging both the differential diagnosis and staging. The endometrial biopsy of a 77-year-old woman admitted to our hospital for endometrial bleeding showed diffuse necrotic material and squamous cell carcinoma, which could have been mistaken for cervical squamous cell carcinoma because the neoplastic cells displayed p16 block-type overexpression, p53 wild-type immunoreactivity, and cervical involvement 2. Nevertheless, clinical presentation and pathological examination of the uterus and adnexa showed that a bulky tumor measuring 35 mm occupied the uterine cavity. In addition, the tumor infiltrated the deeper half of the myometrium to <1 mm from the serosa, and the left fallopian tube stroma was involved, whereas the cervical stroma was only superficially affected. Histologic examination confirmed the diagnosis of squamous cell carcinoma (Fig. 1) with intratumoral necrosis as neither residual endometrial nor endometrioid adenocarcinoma foci were detected. The immunophenotype of the tumor cells exhibited reactivity to cytokeratin 5, p40, cytokeratin 7, p16 (block-type), PTEN/MMAC; proficient mismatch repair proteins, wild-type p53, and Ki67 (MIB-1) comprised ~60% of the cells. Tests for PAX2, estrogen receptor, progesterone receptor, and PAX8 were negative. Thus, the final diagnosis was PESCC, FIGO (International Federation of Gynecology and Obstetrics) stage IIIA (pT3N0M0).FIG. 1: (A) Left fallopian tube infiltrated by squamous cell carcinoma (hematoxylin and eosin, 40×). (B) Myometrum infiltrated by squamous cell carcinoma (hematoxylin and eosin, 40×). (C) Immunoreactivity for Cytokeratin 5 (40×). (D) p16 block type overexpression (100×).According to the 2020 World Health Organization (WHO) classification, the absence of an endometrioid component and the exclusion of cervical origin are essential and desirable diagnostic criteria for diagnosing this rare entity 3. In our case, there was no evidence of endometrioid carcinoma; however, p16 block-type overexpression and cervical involvement raised doubts regarding the exclusion of the cervical origin of the tumor. The cervical carcinoma staging classification includes the depth of cervical stromal invasion and the dimension of the tumor but clearly states that the extension to the corpus uteri should be disregarded 3,4. Therefore, for the diagnosis of cervical carcinoma the stage and therapeutic approach would have been underestimated. Moreover, although it has been claimed to particularly favor the diagnosis of cervical squamous cell carcinoma 2,3, p16 overexpression has also been found to be positive in PESCCs by different authors, as p16 is not always related to HPV infection 5–7. In conclusion, our case demonstrates that p16 reactivity and cervical involvement may lead to an incorrect diagnosis. Thus, to avoid underestimating staging and treatment, PESCC should be the proper diagnosis for squamous cell carcinomas mainly localized in the corpus uteri.

Objective: Cancer-related diseases pose a substantial public health challenge; however, recent treatments have enhanced patient outcomes. Adherence to therapy is crucial, and research focuses on elucidating the factors that influence it. Limited information exists on medication adherence in cancer patients. This study aims to identify risk factors for non-adherence in a cohort of people with solid and hematological tumors. Participants and Methods: This is a cross-sectional study in which participants were recruited from two Oncologic hospital units in Italy. The inclusion criteria were age >= 18 years, confirmed malignant neoplasm, and active treatment. Data included sociodemographic and clinical-oncological factors. Treatment adherence was assessed through a clinician-based dichotomous scale. Health-related quality of life (HRQoL) was evaluated with the Short Form Health Survey - 12 items (SF-12), satisfaction with care was measured using the Treatment Perception Questionnaire. Results: A total of 263 participants (132 females, 50.2%) was involved in this study. The mean age was 61.2 +/- 13.8. Non-adherence frequency was 9.9%. Factors associated with non-adherence were shorter time since care initiation (<6 months), receiving palliative care, having a solid cancer diagnosis. Non-adherence was higher in solid cancer (12.4%) compared to hematologic cancer (1.6%). In the combination of risk factors, a significant association was found between unemployment/high level of education and non-adherence. Conclusions: The study found a low non-adherence rate to oncological treatments, possibly due to strong psychological and spiritual support. However, individuals with higher education and unemployment showed specific non-adherence risk, necessitating attention to their emotional challenges while facing cancer.

e24020 Background: Aging inevitably leads to an accumulation of senescent cells, and immune system cells aren't an exception. They can contribute to a pro-inflammatory state and be involved in the immune escape of cancer cells through a boosted PD-L1 expression. Immunocheckpoint inhibitors (ICIs) represent the standard of care in several cancer histotypes, and immune-related adverse events (irAEs) seem to be associated with better outcomes. ICIs represent a valid therapeutic agent in elderly patients too. However, there is a lack of data on irAEs and outcomes correlation in this subgroup of patients. This retrospective-prospective study aims to evaluate the relationship between thyroid dysfunction and progression-free survival (PFS) and overall survival (OS) in elderly patients undergoing ICIs. Methods: From January 2019 to January 2023, we retrospectively collected data from 65 elderly patients under treatment with ICIs at the Medical Oncology Unit of the University Hospital and University of Cagliari, Italy. All patients were affected by stage IV disease. The primary endpoint was PFS and the secondary endpoint was overall survival OS. Statistical analyses were performed using the MedCalc Statistical Software Version 20.216. Results: The median age was 76 (± 5,5); 15.38% were female, whereas 84.62% were male. The histologies were: melanoma (26.9%), lung cancer (48.0%), kidney cancer (15.3%), and colorectal cancer (9.8%). Compared to those without thyroid dysfunction during immunotherapy treatment, individuals with thyroid irAE had, at univariate analysis, longer median PFS (68 versus 26 months, p = 0.02, CI 95% 18.0-68.0, HR 0.29 0.10-0.83) and longer median OS (59 versus 39 months, p = 0.04, CI 95% 25.0-90.0 HR 0.50 0.25-0.99). Conclusions: In an era where biomarkers for immunotherapeutic agents are lacking, thyroid dysfunction irAE could be a predictive factor of better PFS and OS in elderly patients affected by cancer of various histology.

Objective: The demanding nature of oncological therapies may affect treatment motivation and adherence, leading to an increased risk of premature death. Exploring the interaction between depressive episodes and treatment adherence is essential, considering how depression may influence patients' willingness to continue treatment. This study aims to investigate the association between depressive episodes, low treatment adherence, and premature death in individuals with cancer. The study also assessed whether low adherence to therapy acted as a mediator in the relationship between depression and the risk of early death. Participants and Methods: This is a 9-month cohort study in which participants were enrolled in two Italian Oncology hospital units. The Patient Health Questionnaire (PHQ-9) was used for depression screening. Stratified analyses were conducted to explore the relationship between depression, low adherence, and premature death. Results: Out of 263 subjects, depressive episode frequency was 48.2% and low adherence was 9.9%. After 9 months, 13.7% had died. There was a significative association between experiencing a depressive episode (RR=2.14, 95% CI: 1.08-4.39) and low adherence (RR=2.2, 95% CI: 1.01-4.48) upon cohort entry and being deceased at month 9 of observation. The risk associated with depression was found to persist even after accounting for the level of adherence to therapy through standardization (MH-OR=3.11; 95% CI: 1.52-6.34). Conclusions: Individuals with cancer who experience a depressive episode or demonstrate low adherence to therapy are at risk for premature death. Early intervention targeting depressive symptoms and treatment adherence may improve oncological-related outcomes.

Background:When physicians confront a serious personal illness, they may discover that the transition to the "sick" role is challenging and not easy. We conducted a qualitative study in which a group of doctors with cancer (DP) was compared with a group of patients with cancer, not doctors (NDP) but with a degree of education, qualifications, and a professional role comparable to that of a doctor.Objectives:The main objective was to evaluate the effect of the diagnosis and the treatment of cancer on both the patient's personal and professional life. It was also designed to understand the effect that the experience of cancer may have on the subsequent clinical practice of DP.Methods:The eligibility criteria included diagnosis of tumors of different sites and at any stage of disease treated with local (surgery, radiotherapy) or systemic (chemotherapy, hormonal, target) therapies or a combination of both; patients actively working. A semi-structured interview was used to collect information about the patient's cancer experiences. In both groups, six main themes and ten subthemes were identified.Results:From July to November 2021, 59 patients were enrolled in the study. Among them, 29 were DP and 30 were NDP. The median age and gender were 55.9 years ± 9.3 SD (range 38-82 y), M/F ratio 12/17 for DP, and 56.3 years ± 8.9 SD (range 40-83 y), M/F ratio 11/19 for NDP, respectively. The main themes were: theme 1, practical aspects related to diagnosis: most of the DP did not encounter difficulties in performing the tests necessary to confirm the diagnosis of cancer, unlike what was observed in NDP. Theme 2, cancer diagnosis experience: Many DP and NDP felt prepared for their own cancer experience. Two-thirds of DP already knew their cancer prognosis from their previous background knowledge and one-third of NDP did not want to discuss the prognosis in depth with their referring oncologists for the fear of learning that their cancer had a poor prognosis. Theme 3, treatment experience: for many DP, having a professional background contributed to more active participation in care and also in the management of side effects of treatments. Most NDP were satisfied with the treatment received in the hospital and the relationship with the health professionals. Theme 4, changes in work: None of the patients from both the groups stopped working permanently or lost their job because of the disease. A higher number of DP and NDP reported a loss of interest in their job. Theme 5, changes in personal/family life and friendships: more than half of the patients in both groups developed a new perspective on their private lives. Theme 6, comfort from faith: most of the patients in both groups who followed a faith, found comfort in that faith. For DP only, we explored the theme of the change in the doctor/patient relationship. Important findings from our study included positive changes in the doctor's clinical practice including having a more empathic relationship with patients, greater consideration of the psychological impact of cancer, and greater attention to certain symptoms of cancer reported by patients.Conclusion:This study suggests the need to know the special needs of professional patients, in particular, related to the emotional difficulties, maintenance of privacy, and the need for support on their return to work. These results can help to foster improvements in current cancer care practices.

The evaluation of circulating tumor DNA (ctDNA) is increasingly integrated into the management of diagnosis and treatment of gastrointestinal cancer as it represents an innovative and minimally invasive biomarker that could allow us to reach clinical needs not met yet in randomized clinical trials.Recent research provided an interesting overview of the role of circulating tumor DNA in gastric, biliary, liver, pancreatic, and colorectal cancer.Data regarding upper gastrointestinal tumors are currently not practice changing.Tumor detection rates are low in the early stages, while in advanced stages ctDNA is useful for molecular tracking evaluation.Most of the evidence comes from colorectal cancer studies, where ctDNA was evaluated both in the early and advanced stages with the postsurgery minimal residual disease assessment and the response assessment, respectively.ctDNA qualifies as a promising tool in the era of precision medicine, with potential applications in the entire management of gastrointestinal cancer patients.Further evidence is needed to establish which setting may be influenced greatly by liquid biopsy in clinical practice.

Introduction/Background Sentinel lymph node (SLN) mapping with indocyanine green (ICG) has become the standard of care in apparent early-stage endometrial cancer. The aim of this study is to evaluate the possible risk factors (RFs) for lymph-nodal metastases, differentiating by the type of metastasis. Methodology This is an observational single-center retrospective study. We reviewed 96 patients with a diagnosis of apparent early-stage endometrial cancer submitted to hysterectomy with salpingo-oophorectomy and SLN mapping from December 2015 to March 2022. Possible RFs for nodal metastasis were considered including clinical (age, BMI), and biochemical (CA125, CA 19.9, HE-4) parameters, anatomopathological characteristics (Myometral invasion – MI, Lymphovascular space invasion (LVSI), grade, histotype) and immunohistochemical findings (L1CAM, Ki67, estrogen receptor – ER, progesterone receptor- PR). Odds ratios (ORs) were calculated, and then RFs were confronted with logistic regression. Results Overall detection rate was 94.8%, 83.3% bilateral, and 11.5% unilateral. We removed 181 suspected SLNs. The preponderance of SLNs was found at the external iliac and interiliac stations (69%). 7 patients had macrometastases, 5 micrometastases, and 7 ITCs. Higher ER percentage resulted in a protective factor (PF) for lymph nodal metastasis. MI more than 50%, LVSI, and p53 positivity resulted in RFs for lymph nodal metastases. Histotype, age, and L1CAM showed a slight, not significant, correlation as possible RFs. The multivariate multinomial analysis didn't find any statistically significant differences between the RFs and the type of metastasis. Conclusion Our study shows a good SLN detection rate in line with the literature. The multivariate multinomial analysis shows that there are no differences in the RFs for the different types of metastases suggesting that these entities are a pathological continuum. Further studies are needed.

Aging leads to several changes concerning the immune system activity too. This process is known as “immunosenescence” and it can alter the immune response, especially T-cells response. However, there is lack of data about the response to immunotherapy regimen in elderly patients as well as a predictive factor of response. This retrospective study aims to evaluate the association between the lymphocytes/monocytes ratio (LMr) as a factor of better outcomes.

Low-grade stage I endometrioid endometrial carcinomas should have an excellent prognosis, but a small subset of these cancers can relapse. The search for putative immunohistochemical prognostic markers for relapse in low-risk/low-grade endometrioid endometrial cancers remains open. Among the candidate molecules that may implicate the roles of immunohistochemical risk markers, we focused our attention on human epididymis protein 4 (HE4) after a review of the literature. Few authors have devoted themselves to this topic, and none have found a correlation between the tissue expression of HE4 and the molecular classification of endometrial cancer. Five different variants of HE4 mRNA and multiple protein isoforms of HE4 were identified many years ago, but current HE4 assays only measure the total HE4 expression and do not distinguish the different proteins encoded by different mRNA variants. It is important to have an approach to distinguish specific variants in the future.

As underlined in the minireview by Blomstrand et al, given the poor prognosis and the paucity of data on a therapeutic sequence in pancreatic ductal adenocarcinoma (PDAC), additional randomized controlled trials and real-world evidence studies addressing current and novel regimens are needed. The real-world outcomes of first-line chemotherapy regimens such as FOLFIRINOX and gemcitabine/nab-paclitaxel are thoroughly reviewed and seem to be largely generalizable in a real-world context. Regarding second-line chemotherapy, the key question about the optimal sequence of regimens remains uncertain. Precisely in this setting, it is therefore useful to encourage the implementation of clinical studies that may contribute to the scarcity of data available up to now. We report our experience with a small group of patients treated with second-line liposomal irinotecan (nal-IRI) plus 5-fluorouracil and leucovorin. To improve the treatment of patients affected by PDAC, it is useful to identify subgroups of patients who may benefit from target treatments (e.g., BRCA mutant) and it is also important to focus on any prognostic factors that may affect the survival and treatment of these patients.

Background Aging is marked by a progressive rise in chronic diseases with an impact on social and healthcare costs. Physical activity (PA) may soothe the inconveniences related to chronic diseases, has positive effects on the quality of life and biological rhythms, and can prevent the decline in motor functions and the consequent falls, which are associated with early death and disability in older adults. Methods We randomized 120 over-65 males and females into groups of similar size and timing and will give each either moderate physical activity or cultural and recreational activities. Being younger than 65 years, inability to participate in physical activity for any medical reason, and involvement in a massive program of physical exercise are the exclusion criteria. The primary outcome measures are: quality of life, walking speed, and postural sway. Participants are tested at baseline, post-treatment, and 6-month (24 weeks) and 12-month (48 weeks) follow-ups. Discussion This study aims at improving the quality of life, wellness, and cognitive functioning in the elderly through a low-cost affordable program of moderate physical activity. Given the growing aging of the world population and the social and economic burden of disability in the elderly, our results might have a major impact on future practices. Trial registration ClinicalTrials.gov NCT03858114 . Registered on 28 February 2019.

Key histologic and immnohistochemical features for a correct diagnosis of vascular epithelioid tumors.

BACKGROUND:the aim was to verify the association between Major Depressive Disorders (MDD) and the risk of premature death in people with oncological diseases, and to collect evidence about the causality of a possible association from a longitudinal perspective.DESIGN AND METHODS:it is a cohort study lasting 9 months, involving people with solid or hematologic cancers. The assessment was conducted by an ad hoc form to collect socio-demographic and clinical-oncological data, the PHQ-9 to screen MDD (cut-off ≥10) and the SF-12 to evaluate HRQoL. Relative Risk (RR) of early death between MDD exposed and not-exposed and Kaplan-Meier survival were carried out.RESULTS:people exposed to MDD during the follow-up were 107/263 (40.7%). Among them, 36 deceased during the observation period. Overtime, having MDD and death' occurrence showed a strong association (RR=2.15; 95% CI (1.10-4.20); χ²=5.224, p=0.0022), confirmed by Kaplan-Meier survival analysis (χ²=4.357, p=0.037). Among people who died, there was not any association between MDD, age, gender, HRQoL, cancer stage and site.CONCLUSIONS:the study confirms the association between MDD and early death in people with cancer. The absence of any association between the onset of MDD and advanced stage of cancer may suggest that it could be due to the consequences of MDD in worsening the clinical conditions related to cancer. The findings point out the relevance of MDD' early detention among people with cancer.

Background: Physical activity in the elderly is recommended by international guidelines to protect against cognitive decline and functional impairment. Objective: This Randomized Controlled Trial (RCT) was set up to verify whether medium-intensity physical activity in elderly people living in the community is effective in improving cognitive performance. Design: RCT with parallel and balanced large groups. Setting: Academic university hospital and Olympic gyms. Subjects: People aged 65 years old and older of both genders living at home holding a medical certificate for suitability in non-competitive physical activity. Methods: Participants were randomized to a 12-week, 3 sessions per week moderate physical activity program or to a control condition focused on cultural and recreational activities in groups of the same size and timing as the active intervention group. The active phase integrated a mixture of aerobic and anaerobic exercises, including drills of “life movements”, strength and balance. The primary outcome was: any change in Addenbrooke's Cognitive Examination Revised (ACE-R) and its subscales. Results: At the end of the trial, 52 people completed the active intervention, and 53 people completed the control condition. People in the active intervention improved on the ACE-R (ANOVA: F(1;102)=4.32, p=0.040), and also showed better performances on the memory (F(1;102)=5.40 p=0.022) and visual-space skills subscales of the ACE-R (F(1;102)=4.09 p=0.046). Conclusion: A moderate-intensity exercise administered for a relatively short period of 12 weeks is capable of improving cognitive performance in a sample of elderly people who live independently in their homes. Clinical Trials Registration No: NCT03858114